Smith & Nephew plc Stock Mexican S.E.

Equities

SN1 N

GB0009223206

Medical Equipment, Supplies & Distribution

End-of-day quote Mexican S.E. 06:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
215.6 MXN +7.91% Intraday chart for Smith & Nephew plc 0.00% -0.13%
Sales 2024 * 5.82B 97.71B Sales 2025 * 6.12B 103B Capitalization 10.89B 183B
Net income 2024 * 541M 9.09B Net income 2025 * 694M 11.66B EV / Sales 2024 * 2.31 x
Net Debt 2024 * 2.56B 42.92B Net Debt 2025 * 2.23B 37.44B EV / Sales 2025 * 2.14 x
P/E ratio 2024 *
21.2 x
P/E ratio 2025 *
16.2 x
Employees 18,452
Yield 2024 *
3.04%
Yield 2025 *
3.41%
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.91%
Current month+7.91%
1 month+7.91%
3 months-0.13%
6 months-0.13%
Current year-0.13%
More quotes
1 month
215.59
Extreme 215.59
215.59
Current year
199.78
Extreme 199.78
236.21
1 year
199.78
Extreme 199.78
236.21
3 years
199.78
Extreme 199.78
437.25
5 years
199.78
Extreme 199.78
440.50
10 years
199.78
Extreme 199.78
440.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-03-31
Director of Finance/CFO 56 Nov. 30
Compliance Officer - 99-03-31
Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Director/Board Member 62 23-09-13
Chairman 63 23-04-25
More insiders
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows: - orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders); - sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.; - wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc. The United States accounts for 53.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.48 USD
Average target price
16.36 USD
Spread / Average Target
+31.11%
Consensus